Trabedersen
Based on 1 publication(s) in Google Scholar
Trabedersen (AP 12009) is an orally active synthetic antisense phosphorothioate oligodeoxynucleotide that selectively targets human TGFβ2 mRNA. Trabedersen blocks TGFβ2 protein production, enters the nucleus without a transfection vector, and exerts dose-dependent antitumor effects. By reversing TGFβ2-induced immunosuppression and enhancing immune cytotoxicity, Trabedersen exhibits significant antiproliferative, antimigratory, and antimetastatic activities, with favorable safety profiles. Trabedersen is widely used in research related to various solid tumors, including anaplastic astrocytoma, glioblastoma, colorectal tumor, and melanoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 91.24%
- CAS No.: 925681-61-4
- Masse moléculaire:5768.70
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Trabedersen
More
Activité biologique
Description
In Vitro
Trabedersen (1, 5, 10 μM) reduces TGFβ2 secretion by 49-73% and cell proliferation by 24-41%, inhibits migration, and enhances LAK cell-mediated cytotoxicity in human high-grade astrocytoma (III/IV) cells[1].
Trabedersen inhibits TGFβ2 secretion by 43%, reduces cell proliferation by up to 77%, blocks migration, and increases LAK cell cytotoxicity 4-fold in human pancreatic cancer cell lines (Hup-T3, PA-TU 8902)[1].
Trabedersen (1-80 μM; 7 days) potently suppresses TGF-β2 secretion from human pancreatic cancer Hup-T3 cells, with an IC50 of 1.7 μM and complete inhibition at concentrations ≥60 μM after 7 days of treatment[3].
Trabedersen (2.5-80 μM; 7 days) strongly inhibits proliferation of human pancreatic cancer Hup-T3 cells, with an IC50 of 4.6 μM and >90% inhibition at 40 μM after 7 days of treatment[3].
Trabedersen (5 μM; up to 7 days) completely inhibits migration of human pancreatic cancer PA-TU-8902 cells in a spheroid model when treated with 5 μM for up to 7 days[3].
Trabedersen (200 nM, 5 μM; 6 h, variable) efficiently reverses TGF-β2-mediated immunosuppression of human pancreatic cancer Hup-T3 cells, resulting in significantly increased LAK cell-mediated cytotoxicity against Hup-T3 target cells[3].
Trabedersen (10-80 μM) potently inhibits TGF-β2 secretion in human glioblastoma multiforme cells, with 10 μM trabedersen acting to a greater extent than 80 μM trabedersen[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Hup-T3 cells
-
Concentration:1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM
-
Incubation Time:7 days
-
Result:Inhibited cell proliferation, and completely blocked migration of pancreatic cancer cells.
In Vivo
Trabedersen (30-1000 mg/kg; intravenous injection; single bolus dose) is well tolerated in mice and rats at single intravenous bolus doses up to 100 mg/kg, with an LD50 value of 706 mg/kg in mice and 1175 mg/kg in rats[1].
Continuous intravenous infusion of Trabedersen at a dose of 1 mg/kg/day is well tolerated in rats and monkeys, whereas continuous infusion at higher doses induces reversible inflammation and tissue damage; intravenous infusion at a dose of 8 mg/kg every other day for 4 weeks is also well tolerated in monkeys[1].
In cynomolgus monkeys, trabedersen sodium (5-160 mg/kg; intravenous infusion; 2 h duration; single dose) is well tolerated at intravenous doses up to 20 mg/kg over a 2-hour infusion with respect to cardiovascular and complement activation endpoints; it is well tolerated at doses below 5 mg/kg with respect to hematological indices[1].
Trabedersen (0.25-50 mg/kg; i.p.; three times per week; approximately 32-35 days) sodium exhibits potent dose-dependent antitumor activity in orthotopic xenograft melanoma mouse models, reduces lung metastasis, and shows evidence of immunomodulatory effects as well as cellular/nuclear uptake; among these, the 50/16 mg/kg dosing regimen significantly reduces the average tumor weight to 0.395 g[2].
Trabedersen significantly reduces the tumor weight, tumor cell proliferation level, tumor vascularization degree, and incidence of lymph node metastasis of primary pancreatic cancer in orthotopic xenograft mouse models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eight-week-old male athymic nude mice (BALB⁄Cnu ⁄nu) bearing human pancreatic cancer cells[2].
-
Dosage:Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week.
-
Administration:Intraperitoneal (i.p.) injection; three times a week; for 27 days
-
Result:Significantly reduced tumor growth, lymph node metastasis and angiogenesis.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 925681-61-4
-
Appearance Solid
-
Masse moléculaire 5768.70
-
Color White to off-white
-
SMILES
[Trabedersen]
-
Synonyms
AP 12009
-
Sequence
DNA, d(P-thio)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
MedComm (2020)
Transforming Growth Factor Beta2 Promotes Migration and Inhibits the Proliferation of Gastric Cancer Cells by Regulating the pSmad2/3-NDRG1 Signaling Pathway. [Abstract]2025 Mar 27;6(4):e70148. PMID: 40151835
Solvant et solubilité
In Vitro:
H2O : 100 mg/mL (17.33 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Références
[3]. Schlingensiepen KH, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011;102(6):1193-1200. [Content Brief]
[4]. Bogdahn U, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132-142. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.1733 mL | 0.8667 mL | 1.7335 mL | 4.3337 mL |
| 5 mM | 0.0347 mL | 0.1733 mL | 0.3467 mL | 0.8667 mL | |
| 10 mM | 0.0173 mL | 0.0867 mL | 0.1733 mL | 0.4334 mL | |
| 15 mM | 0.0116 mL | 0.0578 mL | 0.1156 mL | 0.2889 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.